Assessment of SF3B1 Expression as a Prognostic Marker for Neoadjuvant Chemotherapy Response in Stage III Triple-Negative Breast Cancer

doi:10.61882/rbmb.13.4.570

Reports of Biochemistry & Molecular Biology

Assessment of SF3B1 Expression as a Prognostic Marker for Neoadjuvant Chemotherapy Response in Stage III Triple-Negative Breast Cancer — Reports of Biochemistry & Molecular Biology — RBMB